Novotalk
Provides the first end-to-end digital therapy for people with speech disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
N/A | Seed | ||
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 50 % | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Novotalk operates in the digital health sector, focusing on improving speech fluency for individuals who stutter. The company offers a comprehensive digital platform that combines personalized daily practice routines with professional guidance and emotional support. Novotalk primarily serves individuals who have struggled with stuttering, providing them with tools to improve their speech fluency and maintain long-term results. The platform is designed to be user-friendly, allowing clients to decide when and how long to practice, making it easier to integrate into their daily lives. Novotalk's business model is subscription-based, generating revenue through monthly or annual fees paid by users for access to the platform and its resources. The market for speech therapy and fluency improvement is substantial, with a significant number of individuals seeking effective, sustainable solutions for speech disorders. By leveraging technology, Novotalk addresses this need with a scalable, accessible solution that can reach a global audience.
Keywords: speech fluency, stuttering, digital health, personalized practice, professional guidance, emotional support, user-friendly, subscription-based, sustainable results, global reach.